Pyry is a computational biologist and biomedical engineer working at the interface of human genetics and translational medicine. During his PhD with Profs. Samuli Ripatti and Ida Surakka, he showed that loss-of-function variants in ANGPTL8 are associated with substantially lower odds of coronary artery disease, without clear evidence of harmful side effects across a wide range of health outcomes. This genetic evidence has helped motivate therapeutic interest in the ANGPTL3/8 lipid pathway, including phase 1 clinical evaluation of a monoclonal antibody targeting the ANGPTL3/8 complex. He later joined the SPARK Finland biotech incubator, developing a platform to identify disease-specific antigens for safer and more effective immunotherapies. He is now a postdoctoral researcher in the Ewald and Coorens labs at EMBL-EBI, investigating carcinogen modes of action and biomarkers that precede neoplasia.